Predict your next investment

Corporation
HEALTHCARE | Drug Development
junshipharma.com

See what CB Insights has to offer

Business Relationships

10

Service Providers

3

Shanghai Junshi Biosciences Service Providers

6 Service Providers

Shanghai Junshi Biosciences has 6 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

IPO - II

Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

IPO - II

Subscribe to see more

Subscribe to see more

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Shanghai Junshi Biosciences Partners & Customers

10 Partners and customers

Shanghai Junshi Biosciences has 10 strategic partners and customers. Shanghai Junshi Biosciences recently partnered with AstraZeneca on March 3, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

3/1/2021

Licensee

AstraZeneca

United Kingdom

Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

Junshi Biosciences and AstraZeneca will continue to explore overseas business collaboration including the emerging markets and actively explore the possibility of expanding the depth and breadth of future collaborations .

5

2/1/2021

Licensor

Coherus BioSciences

United States

Coherus BioSciences To Expand Late-stage Pipeline To Immuno-oncology With In-license Of Junshi Biosciences' PD-1, Toripalimab, In United States And Canada

In February 2021 , Coherus BioSciences , Inc. and Junshi Biosciences announced a collaboration in which Coherus BioSciences , Inc. would in-license toripalimab , an anti-PD-1 antibody , in the United States and Canada .

13

8/20/2020

Partner

Impact Therapeutics

China

Junshi Biosciences And Impact Therapeutics Establish Joint Venture To Develop PARP Inhibitor Senaparib (IMP4297) In China

SHANGHAI and NANJING , China , Aug. 20 , 2020 -LRB- GLOBE NEWSWIRE -RRB- -- Junshi Biosciences -LRB- HKEX : 1877 ; SSE : 688180 -RRB- , a leading innovation-driven biopharmaceutical company dedicated to the discovery , development and commercialization of novel therapies , and Impact Therapeutics , a privately held clinical-stage biopharmaceutical company devoted to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality , annouced today that they reached a strategic agreement to establish a joint venture focusing on the research and development and commercialization of PARP inhibitor , a small moleule anti-tumor agent .

2

7/14/2020

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/13/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/1/2021

2/1/2021

8/20/2020

7/14/2020

7/13/2020

Type

Licensee

Licensor

Partner

Licensor

Partner

Business Partner

AstraZeneca

Coherus BioSciences

Impact Therapeutics

Country

United Kingdom

United States

China

Subscribe to see more

Subscribe to see more

News Snippet

Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

Junshi Biosciences and AstraZeneca will continue to explore overseas business collaboration including the emerging markets and actively explore the possibility of expanding the depth and breadth of future collaborations .

Coherus BioSciences To Expand Late-stage Pipeline To Immuno-oncology With In-license Of Junshi Biosciences' PD-1, Toripalimab, In United States And Canada

In February 2021 , Coherus BioSciences , Inc. and Junshi Biosciences announced a collaboration in which Coherus BioSciences , Inc. would in-license toripalimab , an anti-PD-1 antibody , in the United States and Canada .

Junshi Biosciences And Impact Therapeutics Establish Joint Venture To Develop PARP Inhibitor Senaparib (IMP4297) In China

SHANGHAI and NANJING , China , Aug. 20 , 2020 -LRB- GLOBE NEWSWIRE -RRB- -- Junshi Biosciences -LRB- HKEX : 1877 ; SSE : 688180 -RRB- , a leading innovation-driven biopharmaceutical company dedicated to the discovery , development and commercialization of novel therapies , and Impact Therapeutics , a privately held clinical-stage biopharmaceutical company devoted to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality , annouced today that they reached a strategic agreement to establish a joint venture focusing on the research and development and commercialization of PARP inhibitor , a small moleule anti-tumor agent .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

13

2

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.